@inproceedings{inproceedings, title  = {{Safety of cytotoxic chemotherapy following Radium223-Dichlorid(Ra223)-therapy in the phase 3 ALSYMPCA study in patients with castration resistant prostate cancer (CRPC) metastatic to the bone}},

 url = {{}},

 year = {{2013}},

 month = {{10}},

 author = {{Stroelin P and Haese A and Heinzer H and Steuber T and Sartor O and Coleman RE and Nilsson S and Vogelzang N and Cross A and O'Bryan-Tear G and Staudacher K et al}},

 volume = {{36}},

 journal = {{ONKOLOGIE}},

 pages = {{20-20}},

 note = {{Accessed on 2025/10/10}}}